A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH).

Trial Profile

A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 once daily on Steatohepatitis in Patients with Non-Alcoholic Steatohepatitis (NASH).

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Elafibranor (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms GOLDEN-505
  • Sponsors Genfit
  • Most Recent Events

    • 17 Apr 2016 Results comparing the effect of elafibranor (ELA) 120 mg on plasma lipids and overall population (OP) presented at The International Liver Congress™ 2016
    • 17 Apr 2016 Results of a post-hoc analysis (n=120) presented at The International Liver Congress™ 2016
    • 17 Apr 2016 Results assessing influence of PNPLA3-GG haplotype presented at The International Liver Congress™ 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top